In 2017, Li et al. reported the ability of a combination therapy using tubastatin A, a selective HDAC6 inhibitor, and temozolomide (TMZ), a “cornerstone” compound for the treatment of glioblastoma multiforme, to overcome multidrug resistance issues associated with endoplasmic reticulum stress tolerance in glioma cells. The gene discussed is HDAC6; the disease is central nervous system cancer.